Source:http://linkedlifedata.com/resource/pubmed/id/20956986
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2011-3-17
|
pubmed:abstractText |
Numerous human immunodeficiency virus (HIV)-1 vaccines have been developed over the last three decades, but to date an effective HIV-1 vaccine that can be used for prophylactic or therapeutic purposes in humans has not been identified. The failures and limited successes of HIV-1 vaccines have highlighted the gaps in our knowledge with regard to fundamental immunity against HIV-1 and have provided insights for vaccine strategies that may be implemented for designing more effective HIV-1 vaccines in the future. Recent studies have shown that robust mucosal immunity, high avidity and polyfunctional T cells, and broadly neutralizing antibodies are important factors governing the induction of protective immunity against HIV-1. Furthermore, optimization of vaccine delivery methods for DNA or live viral vector-based vaccines, elucidating the immune responses of individuals who remain resistant to HIV-1 infections and also understanding the core immune responses mediating protection against simian immunodeficiency viruses (SIV) and HIV-1 in animal models following vaccination, are key aspects to be regarded for designing more effective HIV-1 vaccines in the future.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1440-1711
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
89
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
367-74
|
pubmed:meshHeading |
pubmed-meshheading:20956986-AIDS Vaccines,
pubmed-meshheading:20956986-Adaptive Immunity,
pubmed-meshheading:20956986-Animals,
pubmed-meshheading:20956986-Antibodies, Neutralizing,
pubmed-meshheading:20956986-Genetic Vectors,
pubmed-meshheading:20956986-HIV-1,
pubmed-meshheading:20956986-Humans,
pubmed-meshheading:20956986-Immunity, Mucosal,
pubmed-meshheading:20956986-SAIDS Vaccines,
pubmed-meshheading:20956986-T-Lymphocytes,
pubmed-meshheading:20956986-Vaccines, Attenuated
|
pubmed:year |
2011
|
pubmed:articleTitle |
Human immunodeficiency virus-1 vaccine design: where do we go now?
|
pubmed:affiliation |
Department Emerging Pathogens and Vaccines, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia. danushka.wijesundara@anu.edu.au
|
pubmed:publicationType |
Journal Article,
Review
|